vs
Side-by-side financial comparison of BANK OF NOVA SCOTIA (BNS) and Kenvue (KVUE). Click either name above to swap in a different company.
BANK OF NOVA SCOTIA is the larger business by last-quarter revenue ($7.0B vs $3.8B, roughly 1.9× Kenvue). BANK OF NOVA SCOTIA runs the higher net margin — 23.8% vs 8.7%, a 15.1% gap on every dollar of revenue.
The Bank of Nova Scotia, operating as Scotiabank, is a Canadian multinational banking and financial services company headquartered in Toronto, Ontario. One of Canada's Big Five banks, it is the third-largest Canadian bank by assets and deposits. In 2023, the company's seat in Forbes Global 2000 was 88. Scotiabank serves over 25 million customers globally, offering personal and commercial banking, wealth management, corporate and investment services. With 88,000 employees and assets of approxi...
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
BNS vs KVUE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.0B | $3.8B |
| Net Profit | $1.7B | $330.0M |
| Gross Margin | — | 56.5% |
| Operating Margin | — | 14.2% |
| Net Margin | 23.8% | 8.7% |
| Revenue YoY | — | 3.2% |
| Net Profit YoY | — | 12.6% |
| EPS (diluted) | — | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.2B | $3.8B | ||
| Q3 25 | $6.9B | $3.8B | ||
| Q2 25 | $6.6B | $3.8B | ||
| Q1 25 | — | $3.7B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | — | $3.9B | ||
| Q2 24 | — | $4.0B |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.6B | $330.0M | ||
| Q3 25 | $1.8B | $398.0M | ||
| Q2 25 | $1.5B | $420.0M | ||
| Q1 25 | — | $322.0M | ||
| Q4 24 | — | $293.0M | ||
| Q3 24 | — | $383.0M | ||
| Q2 24 | — | $58.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.5% | ||
| Q3 25 | — | 59.1% | ||
| Q2 25 | — | 58.9% | ||
| Q1 25 | — | 58.0% | ||
| Q4 24 | — | 56.5% | ||
| Q3 24 | — | 58.5% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 14.2% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.0% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 3.9% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 22.5% | 8.7% | ||
| Q3 25 | 26.6% | 10.6% | ||
| Q2 25 | 22.4% | 10.9% | ||
| Q1 25 | — | 8.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 9.8% | ||
| Q2 24 | — | 1.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.21 | ||
| Q2 25 | — | $0.22 | ||
| Q1 25 | — | $0.17 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | — | $0.20 | ||
| Q2 24 | — | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4B | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $65.0B | $10.8B |
| Total Assets | $1077.5B | $27.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $6.4B | — | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | $8.6B | $1.1B | ||
| Q2 25 | $7.9B | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.0B |
| Q1 26 | $65.0B | — | ||
| Q4 25 | — | $10.8B | ||
| Q3 25 | $62.4B | $10.6B | ||
| Q2 25 | $63.1B | $10.7B | ||
| Q1 25 | — | $10.1B | ||
| Q4 24 | — | $9.7B | ||
| Q3 24 | — | $10.6B | ||
| Q2 24 | — | $10.2B |
| Q1 26 | $1077.5B | — | ||
| Q4 25 | — | $27.1B | ||
| Q3 25 | $1032.7B | $27.2B | ||
| Q2 25 | $1033.3B | $27.1B | ||
| Q1 25 | — | $26.3B | ||
| Q4 24 | — | $25.6B | ||
| Q3 24 | — | $26.9B | ||
| Q2 24 | — | $26.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.4B | $854.0M |
| Free Cash FlowOCF − Capex | — | $744.0M |
| FCF MarginFCF / Revenue | — | 19.7% |
| Capex IntensityCapex / Revenue | — | 2.9% |
| Cash ConversionOCF / Net Profit | 5.60× | 2.59× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.7B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $9.4B | — | ||
| Q4 25 | — | $854.0M | ||
| Q3 25 | $3.2B | $294.0M | ||
| Q2 25 | $1.8B | $621.0M | ||
| Q1 25 | — | $428.0M | ||
| Q4 24 | — | $793.0M | ||
| Q3 24 | — | $249.0M | ||
| Q2 24 | — | $440.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $744.0M | ||
| Q3 25 | — | $196.0M | ||
| Q2 25 | — | $533.0M | ||
| Q1 25 | — | $249.0M | ||
| Q4 24 | — | $661.0M | ||
| Q3 24 | — | $190.0M | ||
| Q2 24 | — | $350.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.7% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 18.1% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 8.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.9% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 2.3% |
| Q1 26 | 5.60× | — | ||
| Q4 25 | — | 2.59× | ||
| Q3 25 | 1.73× | 0.74× | ||
| Q2 25 | 1.22× | 1.48× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 7.59× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNS
Segment breakdown not available.
KVUE
| Self Care | $1.6B | 42% |
| Essential Health | $1.1B | 30% |
| Skin Health And Beauty | $1.0B | 28% |
